(Q36613990)

15 August 2017

1 reference

title

Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma (English)

1 reference

15 August 2017

3

Kenneth C Anderson

1 reference

15 August 2017

Noopur Raje

1

1 reference

15 August 2017

Teru Hideshima

series ordinal

2

1 reference

15 August 2017

publication date

1 September 2006

1 reference

Expert Review of Anticancer Therapy

15 August 2017

published in

1 reference

15 August 2017

volume

6

1 reference

15 August 2017

issue

9

1 reference

15 August 2017

page(s)

1239-1247

1 reference

Advances in biology of multiple myeloma: clinical applications

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1239

21 January 2018

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1239

Identification and validation of novel therapeutic targets for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1239

Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1239

Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1239

Chiral inversion and hydrolysis of thalidomide: mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1239

(S)-form of alpha-methyl-N(alpha)-phthalimidoglutarimide, but not its (R)-form, enhanced phorbol ester-induced tumor necrosis factor-alpha production by human leukemia cell HL-60: implication of optical resolution of thalidomidal effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1239

Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1239

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1239

Akt phosphorylation site found in human caspase-9 is absent in mouse caspase-9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1239

NF-kappa B as a therapeutic target in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1239

Molecular mechanisms of novel therapeutic approaches for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1239

Duration of immunosuppressive treatment for chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1239

Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1239

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1239

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1239

Anti-angiogenic effects of thalidomide: expression of apoptosis-inducible active-caspase-3 in a three-dimensional collagen gel culture of aorta

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1239

Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1239

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1239

Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1239

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1239

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1239

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1239

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1239

S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1239

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1239

Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1239

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1239

VAD-based regimens as primary treatment for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1239

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1239

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1239

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1239

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1239

Thalidomide and hematopoietic-cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1239

The evolution of thalidomide and its IMiD derivatives as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1239

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1239

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1239

Toxicity and Teratogenicity of Optical Isomers of Thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.9.1239

10.1586/14737140.6.9.1239

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference